Selection of Germline Genetic Testing Panels in Patients With Cancer: ASCO Guideline
Source : https://pubmed.ncbi.nlm.nih.gov/38759122/
Patients should have a family history taken and recorded that includes details of cancers in first- and second-degree relatives and the patient's ethnicity. When more than one gene is relevant...
ASCO supports that all patients with tumor pathogenic variants in select genes, including RET, should be offered germline testing.
Clinical Activity of Selpercatinib in RET-Mutant Pheochromocytoma
Source : https://pubmed.ncbi.nlm.nih.gov/38661071/
These data support selpercatinib as an effective therapy against RET-mutant pheochromocytoma, adding to the diversity of RET-activated tumor types that may benefit from targeted RET inhibition.
Of 6 patients, 4 had a partial/complete response and 2 had stable disease per independent review committee.
Spontaneous and Treatment-Related Changes of Serum Calcitonin in Medullary Thyroid Cancer: Long-Term Experience in a Patient With Multiple Endocrine Neoplasia Type 2B
Source : https://pubmed.ncbi.nlm.nih.gov/38709988/
This case of MEN2B medullary thyroid cancer with long-term survival presents how the effectiveness of different treatment modalities can be estimated using log-transformed calcitonin levels. Furthermore, our experience supports the...
The best treatment response was observed with selpercatinib, which was associated with an initial large drop followed by a decreasing calcitonin trajectory over 514 days without any major side effects.
RET Rearrangement as a Mechanism of Resistance to ALK-TKI in Non-Small Cell Lung Cancer Patient With EML4-ALK Fusion: a Case Report
Source : https://pubmed.ncbi.nlm.nih.gov/38698976/
Patients with non-small cell lung cancer (NSCLC) and anaplastic lymphoma kinase (ALK) mutations have previously derived substantial benefits from ALK tyrosine kinase inhibitors (ALK-TKIs). However, resistance may develop in some...
This case underscored that a dual-target therapy involving ALK inhibitors, specifically ensartinib and pralsetinib, could be a viable approach in cases of RET-rearranged lung cancer with concurrent targetable ALK mutations.
Timing and Ideal Patient for an Appropriate Search for Somatic RET Mutation in Medullary Thyroid Cancer
Source : https://pubmed.ncbi.nlm.nih.gov/38709990/
RET somatic mutation analysis in sporadic MTC should be guided by postoperative evaluation results.
The timing of somatic RET mutation analysis and the identification of the ideal patient with sporadic medullary thyroid cancer in whom it should be performed may be based on the response at the first postoperative evaluation.